{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:33:37Z","timestamp":1781530417268,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.amjmed.2005.09.014","type":"journal-article","created":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T12:59:32Z","timestamp":1134651572000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S","title":["Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy\u2013Thrombolysis in Myocardial Infarction 22 (PROVE IT\u2013TIMI 22) trial"],"prefix":"10.1016","volume":"118","author":[{"given":"Jean","family":"Rouleau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.09.014_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease","volume":"344","year":"1994","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2005.09.014_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.09.014_bib5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA)","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2005.09.014_bib6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2005.09.014_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals","volume":"360","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2005.09.014_bib8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib9","first-page":"921","article-title":"Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease","volume":"169","author":"Genest","year":"2003","journal-title":"CMAJ."},{"key":"10.1016\/j.amjmed.2005.09.014_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.09.014_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2003.10.001","article-title":"European guidelines on cardiovascular disease and prevention in clinical practice","volume":"171","author":"De Backer","year":"2003","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.amjmed.2005.09.014_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/01.CIR.97.15.1436","article-title":"Statin trials and goals of cholesterol-lowering therapy","volume":"97","author":"Grundy","year":"1998","journal-title":"Circulation."},{"key":"10.1016\/j.amjmed.2005.09.014_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0091-7435(81)90062-1","article-title":"Multiple risk factor intervention trial (MRFIT)","volume":"10","author":"Cohen","year":"1981","journal-title":"Prev Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0735-1097(98)00522-1","article-title":"Influence of baseline lipids on effectiveness of pravastatin in the CARE [Cholesterol and Recurrent Events] Trial","volume":"33","author":"Pfeffer","year":"1999","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2005.09.014_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation."},{"key":"10.1016\/j.amjmed.2005.09.014_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP)","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2005.09.014_bib17","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.amjmed.2005.09.014_bib18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.09.014_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.09.014_bib20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","article-title":"ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non\u2013ST-segment elevation myocardial infarction\u2014summary article","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2005.09.014_bib21","first-page":"439","article-title":"High-sensitivity C-reactive protein","volume":"29","author":"Bassuk","year":"2004","journal-title":"Curr Probl Cardiol."},{"key":"10.1016\/j.amjmed.2005.09.014_bib22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","article-title":"High-sensitivity C-reactive protein","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.amjmed.2005.09.014_bib24","doi-asserted-by":"crossref","first-page":"13043","DOI":"10.1073\/pnas.192399699","article-title":"C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand","volume":"99","author":"Chang","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.amjmed.2005.09.014_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJMe048326","article-title":"Statins for atherosclerosis\u2014as good as it gets?","volume":"352","author":"Ehrenstein","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib27","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.09.014_bib28","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jama.292.11.1365","article-title":"High-dose statins in acute coronary syndromes","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.09.014_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.amjmed.2005.09.014_bib30","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.09.014_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2004.06.003","article-title":"Design and baseline characteristics of the Incremental Decrease in End Points Through Aggressive Lipid Lowering study","volume":"94","author":"Pedersen","year":"2004","journal-title":"Am J Cardiol."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305008090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305008090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:39:14Z","timestamp":1757579954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305008090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0002934305008090"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.014","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy\u2013Thrombolysis in Myocardial Infarction 22 (PROVE IT\u2013TIMI 22) trial","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}